Q-omics provides the consensus-scored TMEM35B profile across patient tissues and cancer cell-line models. TMEM35B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM35B is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, TMEM35B RNA expression shows 19,503 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where TMEM35B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM35B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM35B survival associations across molecular data types. TMEM35B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM35B RNA expression–survival associations across cancer types. High TMEM35B expression shows unfavorable associations in UVM, LGG, KIRP and CESC, but favorable associations in KIRC and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM35B RNA expression.
This table summarizes TMEM35B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM35B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM35B shows lower tumor expression in KICH, LUAD, LUSC and UCEC and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher TMEM35B RNA expression in tumor versus normal tissue (log2 FC = +1.036, t-test p < 0.001).
This table shows molecular features associated with TMEM35B in patient tissues and cancer cell lines. In patient samples, TMEM35B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM35B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
